Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jin-Ching Lin

Showing results (91-100 of 135) with videos related to

Pageof 14
Sort By:
Cancer|October 16, 2012
Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levelsWen-Yi Wang, Chih-Wen Twu, Hsin-Hong Chen, et al.
BMC Cancer|January 29, 2016
Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinomaGuopei Zhu, Jin-Ching Lin, Sung-Bae Kim, et al.
Cancers|September 28, 2023
Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell CarcinomaYu-Chieh Ho, Yuan-Chun Lai, Hsuan-Yu Lin, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal CarcinomaYu-Pei Chen, Lei Chen, Wen-Fei Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2023
Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patientsJing Feng Zong, Po-Ju Lin, Hsiao-Hui Tsou, et al.
Scientific Reports|March 24, 2021
Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapyYu-Chieh Ho, Yuan-Chun Lai, Hsuan-Yu Lin, et al.
Targeted Oncology|January 29, 2024
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)Hung-Ming Wang, Pei-Jen Lou, Muh-Hwa Yang, et al.
Oral Oncology|February 11, 2021
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R Adkins, Jin-Ching Lin, Assuntina Sacco, et al.
European Journal of Haematology|June 25, 2014
Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphomaHui-Jen Tsai, Sheng-Fung Lin, Chu-Chih Chen, et al.
The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.
Pageof 14

Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
Cancer|October 16, 2012
Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levelsWen-Yi Wang, Chih-Wen Twu, Hsin-Hong Chen, et al.
BMC Cancer|January 29, 2016
Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinomaGuopei Zhu, Jin-Ching Lin, Sung-Bae Kim, et al.
Cancers|September 28, 2023
Cardiac Dose Predicts the Response to Concurrent Chemoradiotherapy in Esophageal Squamous Cell CarcinomaYu-Chieh Ho, Yuan-Chun Lai, Hsuan-Yu Lin, et al.
International Journal of Radiation Oncology, Biology, Physics|June 8, 2017
Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal CarcinomaYu-Pei Chen, Lei Chen, Wen-Fei Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2023
Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patientsJing Feng Zong, Po-Ju Lin, Hsiao-Hui Tsou, et al.
Scientific Reports|March 24, 2021
Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapyYu-Chieh Ho, Yuan-Chun Lai, Hsuan-Yu Lin, et al.
Targeted Oncology|January 29, 2024
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08)Hung-Ming Wang, Pei-Jen Lou, Muh-Hwa Yang, et al.
Oral Oncology|February 11, 2021
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R Adkins, Jin-Ching Lin, Assuntina Sacco, et al.
European Journal of Haematology|June 25, 2014
Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphomaHui-Jen Tsai, Sheng-Fung Lin, Chu-Chih Chen, et al.
The Lancet. Oncology|January 30, 2017
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trialDenis Soulières, Sandrine Faivre, Ricard Mesía, et al.
Pageof 14